Solid Biosciences Inc. (SLDB) stock
SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.44+0.09 (+1.42%)
Close on Nov 19, 2026Market cap $690.53MP/E –Yield –
Solid Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Solid Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$187.81M. For fiscal 2025 it was -$157.44M. The highest annual figure on record is -$20.51M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$157.44M | – |
| FY2024 | Dec 31, 2024 | -$100.67M | – |
| FY2023 | Dec 31, 2023 | -$95.70M | – |
| FY2022 | Dec 31, 2022 | -$100.99M | – |
| FY2021 | Dec 31, 2021 | -$79.05M | – |
| FY2020 | Dec 31, 2020 | -$57.50M | – |
| FY2019 | Dec 31, 2019 | -$97.10M | – |
| FY2018 | Dec 31, 2018 | -$77.97M | – |
| FY2017 | Dec 31, 2017 | -$45.50M | – |
| FY2016 | Dec 31, 2016 | -$20.51M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$52.74M | – |
| Q1 FY2026 | Mar 31, 2026 | -$47.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$54.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$33.56M | – |
| Q2 FY2025 | Jun 30, 2025 | -$37.79M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.98M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.85M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.72M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.75M | – |
| Q1 FY2024 | Mar 31, 2024 | -$25.34M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$28.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$35.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.27M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.53M | -1826.9% |
| Q3 FY2021 | Sep 30, 2021 | -$18.66M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.45M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.40M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.25M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.64M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.15M | – |
| Q1 FY2020 | Mar 31, 2020 | -$29.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -$21.89M | – |
| Q3 FY2019 | Sep 30, 2019 | -$19.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$27.44M | – |
| Q1 FY2019 | Mar 31, 2019 | -$27.88M | – |
| Q4 FY2018 | Dec 31, 2018 | -$22.84M | – |
| Q3 FY2018 | Sep 30, 2018 | -$17.41M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.55M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.17M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.31M | – |
| Q3 FY2017 | Sep 30, 2017 | -$11.10M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.65M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.44M | – |
See a number that looks wrong?